Well Told Grants

Federal grant recipients / Michigan

Federal grants to TSRL, Inc.

Ann Arbor, Michigan · Small businesses · UEI TP74UMNGJDJ1

TSRL, Inc. in Ann Arbor, Michigan received $13.0 million in federal grants from fiscal 2021 to 2025, across 9 awards. Its largest program was Allergy and Infectious Diseases Research, with $9.5 million. In fiscal 2025 it was awarded $3.1 million.

From USAspending.gov award records, updated October 31, 2026.

By year

Federal grants to TSRL, Inc. by fiscal year
Fiscal yearAwardsAmount
FY 20211$952,176
FY 20225$2.7 million
FY 20235$2.9 million
FY 20244$3.3 million
FY 20253$3.1 million

An award funded in several years counts in each of them, so yearly awards add up to more than the five-year total.

Programs that fund TSRL, Inc.

Every program, fiscal 2021 to 2025
ProgramAwardsAmount
Allergy and Infectious Diseases Research 93.8555$9.5 million
Biomedical Research and Research Training 93.8591$1.6 million
Diabetes, Digestive, and Kidney Diseases Extramural Research 93.8471$1.1 million
Cardiovascular Diseases Research 93.8371$394,392
Child Health and Human Development Extramural Research 93.8651$299,620

Awarding agencies

AgencyAwardsAmount
Department of Health and Human Services9$13.0 million

Largest awards

The 9 largest awards by money obligated in fiscal 2021 to 2025
AwardProgramFirst actionAmount
Microneedle delivery of zanamivir for treatment of influenza
ASST_NON_R44AI129122_075 on USAspending
Allergy and Infectious Diseases ResearchMarch 25, 2021$4.0 million
Development of methionyl-trna synthetase inhibitors for gram positive bacterial infections
ASST_NON_R44AI134190_075 on USAspending
Allergy and Infectious Diseases ResearchOctober 14, 2021$3.0 million
Novel, self-applied microarray patch (MAP) of zanamivir for treatment of the flu - abstract yearly influenza epidemics strike millions of people, causing up to 500,000 deaths. Fatality caused by most seasonal influenza viruses is <0.03%, but with significant mortality in the young and the elderly PO
ASST_NON_R44AI179506_075 on USAspending
Allergy and Infectious Diseases ResearchJuly 27, 2023$2.3 million
Development of synthetic high-density lipoproteins for treatment of sepsis - enter the text here that is the new abstract information for your application. This section must be no longer than 30 lines of text. Sepsis represents a major health issue, which claims over 270,000 lives each year in the u
ASST_NON_R44GM145103_075 on USAspending
Biomedical Research and Research TrainingFebruary 9, 2022$1.6 million
Microneedle delivery of trospium chloride optimized for improved tolerance and patient outcomes in overactive bladder disease - abstract overactive bladder (OB) is a disease that afflicts both men and women and is driven by the aging population with a prevalence estimated as high as 39% in the us an
ASST_NON_R44DK143799_075 on USAspending
Diabetes, Digestive, and Kidney Diseases Extramural ResearchSeptember 15, 2025$1.1 million
Novel, safe, efficacious heparin reversal - abstract anticoagulants and their reversal agents are key components of standard of care for managing thrombosis. Heparin in particular is used for thrombosis prevention in multiple clinical indications, including procedures such as cardiopulmonary bypass
ASST_NON_R43HL165961_075 on USAspending
Cardiovascular Diseases ResearchAugust 10, 2022$394,392
Microneedle delivery of trospium chloride optimized for improved tolerance and patient outcomes in overactive bladder disease - abstract overactive bladder (OB) is a disease that afflicts both men and women and is driven by the aging population with a prevalence estimated as high as 39% in the us an
ASST_NON_R43HD109069_075 on USAspending
Child Health and Human Development Extramural ResearchSeptember 19, 2022$299,620
Phase 1 clinical trial to assess the pharmacokinetics, safety and tolerance of a zanamivir transdermal system in healthy subjects - abstract yearly influenza epidemics strike millions of people, resulting in up to 500,000 deaths. Fatalities caused by most seasonal influenza viruses is <0.03%, with s
ASST_NON_U44AI184201_075 on USAspending
Allergy and Infectious Diseases ResearchJuly 10, 2024$292,746
Cell-penetrating antimicrobial therapeutics for treatment of complicated skin and soft tissue infections
ASST_NON_R41AI132102_075 on USAspending
Allergy and Infectious Diseases ResearchSeptember 26, 2022$0

Amounts are net obligations: money committed, minus any amounts taken back. They are not payments. See how our data works.

Questions people ask

How much federal grant money does TSRL, Inc. get?

$13.0 million in 9 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.

Which agency gives TSRL, Inc. the most?

The Department of Health and Human Services, with $13.0 million in 9 awards.

What is TSRL, Inc.'s largest federal grant?

$4.0 million under Allergy and Infectious Diseases Research, with its first action in the period on March 25, 2021. That counts only the money obligated in fiscal 2021 to 2025.

Which federal programs fund TSRL, Inc.?

Its largest are Allergy and Infectious Diseases Research, Biomedical Research and Research Training and Diabetes, Digestive, and Kidney Diseases Extramural Research.

Other grant recipients in Ann Arbor

Largest federal grant recipients in Michigan · Federal grants in Michigan